

1 **Prospective follow-up of New York City residents with e-cigarette, or vaping product use-**
2 **associated lung injury—2020–2021**

3
4 **Short Title: New York City residents with e-cigarette, or vaping product use associated**
5 **lung injury**

6
7
8 Kathryn M. Tannert Niang, MPH^{1*}; Aviva B. Grasso, MPH¹; Indira Debchoudhury, MPH¹; Dena
9 Bushman, MSN, MPH^{2,3^}; John P. Jasek, MPA¹; Monique A. Fairclough, MPH¹; Katherine R.
10 Van Oss, MD, MS³; Shadi Chamany, MD, MPH¹; Kendall D. LaSane, MPH⁴, Sharraine M.
11 Franklin¹, Achala K. Talati, DO, MPH¹

12
13 ¹ Center for Health Equity and Community Wellness, New York City Department of Health and
14 Mental Hygiene, New York, United States of America

15 ² Epidemic Intelligence Service, Division of Scientific Education and Professional Development,
16 CDC, Atlanta, Georgia, United States of America

17 ³ Corewell Health, Women’s Health & Wellness Center, Grand Rapids, Michigan, United States
18 of America

19 ⁴ Department of Health Policy and Management, University of North Carolina Gillings School of
20 Global Public Health, Chapel Hill, North Carolina, United States of America

21
22 * Corresponding author

23 ktannert@health.nyc.gov (KTN)

24
25 ^The findings and conclusions in this report are those of the authors and do not necessarily
26 represent the official position of the Centers for Disease Control and Prevention.

27 **Abstract:**

28 **Background:** A multistate outbreak of e-cigarette, or vaping, product use-associated lung
29 injury (EVALI) occurred in 2019. Because of EVALI’s novelty and severity, the New York City
30 (NYC) Department of Health and Mental Hygiene (DOHMH) prospectively assessed sequelae
31 among NYC residents who received an EVALI diagnosis in 2019.

32 **Methods:** Using existing NYC EVALI surveillance data, DOHMH attempted contact
33 with all living residents who received an EVALI diagnosis in 2019 and conducted 3 waves of
34 telephone interviews during April 2020–March 2021. Interview questions were adapted from the
35 Centers for Disease Control and Prevention’s EVALI case report form and validated surveys.
36 Baseline differences between respondents and nonrespondents were assessed with Chi-square
37 and Fisher’s exact tests; clinical and behavioral characteristics and open-ended responses were
38 summarized.

39 **Results:** In 2019, 53 NYC residents received an EVALI diagnosis; 33 (67%), 14 (29%),
40 and 18 (37%) of 49 living residents participated in the first, second, and third interviews,
41 respectively. Interviews occurred after outpatient diagnosis (6%) or hospital discharge (94%), at
42 a median of 8, 11, and 17 months for each wave. Respondents (N = 33) and nonrespondents (N =
43 16) did not differ by sex, age, hospitalization status or length. Respondents were mostly male
44 (70%), had a median age of 23 years (range: 16–63 years), and all reported using vaping or e-
45 cigarette products (vaping) with tetrahydrocannabinol (88%), nicotine (49%), or cannabidiol
46 (9%) before diagnosis. Respiratory (first and second interviews) and gastrointestinal (third
47 interviews) symptoms were most commonly reported. Sixteen respondents (49%) reported any
48 new diagnosis during follow-up. Fifteen to 29% of respondents reported vaping at each
49 interview; 58%–93% reported recent non-vaped cannabinoid use.

50 **Conclusion:** NYC residents with EVALI reported symptoms throughout the follow-up
51 period, and approximately half reported newly diagnosed health conditions.

52

53 **Introduction**

54 In summer 2019, the Centers for Disease Control and Prevention (CDC), the Food and
55 Drug Administration, and state and local health departments, including New York City (NYC)
56 Department of Health and Mental Hygiene (DOHMH), began investigating reports of severe
57 lung injuries among persons with a history of e-cigarette or vaping product use (vaping). During
58 August 2019–February 2020, CDC reported 2,807 cases of e-cigarette, or vaping, product use-
59 associated lung injury (EVALI) nationwide. This included 127 (5%) that were reported in New
60 York State (NYS) during August 2019-February 2020.[1] During August–December 2019, NYS
61 reported 113 cases, of which 53 (46%) were NYC residents and are the subject of this report.

62 CDC described patients from across the United States who received an EVALI diagnosis
63 mostly were young adult males. These persons had vaped tetrahydrocannabinol (THC), nicotine,
64 or other liquids (e-liquids), and experienced respiratory, gastrointestinal, and constitutional
65 symptoms over the course of a few days to several weeks [1]. Because of reports of
66 rehospitalization and death post-discharge from initial EVALI hospitalization, CDC’s guidance
67 on standards of care evolved between the initial recognition of EVALI in August 2019, and
68 January 2020, when management algorithms were updated. This guidance addressed patients’
69 clinical readiness for hospital discharge, social support and access to mental health and substance
70 use disorder services, best practices for medication adherence, and post-discharge medical
71 follow-up, including with primary care providers and pulmonologists [2].

72 Despite the clinical severity of certain EVALI cases and concerns about the toxicity of
73 vaping products more broadly, [3, 4] the long-term effects of EVALI are not well understood [2,
74 5, 6]. Because of the novelty of EVALI and reports of rehospitalization and death, DOHMH
75 prospectively assessed NYC residents who had received an EVALI diagnosis in 2019. Even with
76 limited knowledge on sequelae of EVALI, we were able to assess changes in symptoms,
77 concomitant diagnoses, healthcare usage, functional and financial consequences, and substance
78 use over time, among this cohort of NYC residents.

79

80 **Methods**

81 **Data Sources**

82 In 2019, potential EVALI cases were identified through passive (reports to poison control
83 centers, NYS Department of Health [DOH], and DOHMH) and active (syndromic) surveillance.
84 At that time, each potential EVALI case was identified and classified using CDC’s 2019 Lung
85 Injury surveillance case definitions [7]. Baseline EVALI surveillance data were collected from
86 provider reports to the NYC Poison Control Center and patient medical records that were
87 obtained directly from NYC hospitals. During April 2020–March 2021, we conducted 3 waves
88 of telephone interviews with surviving NYC residents who had received an EVALI diagnosis in
89 2019 to follow them over time; the list was confirmed with NYS DOH to ensure that all reported
90 cases were included. Before each wave of interviews, a match with the NYC vital statistics death
91 registry was conducted to assess for any recent deaths.

92 We conducted interviews in English or in respondent’s primary language (n = 1, in
93 Mandarin) using a telephone interpreter service. NYC residents who received an EVALI
94 diagnosis were called up to three times during each wave of interviews. For those not reached in

95 the first call attempt, we left voicemails and sent text messages or emails to help schedule
96 interviews. We mailed letters to all persons not reached during the first interview wave,
97 informing them of the surveillance project and requesting their participation. Approximately
98 three months after completing the first wave of interviews, we initiated second interviews with
99 the initial respondents. We also attempted to interview all nonrespondents from the first wave of
100 calls who had not opted out of participation, completing abbreviated first interviews with those
101 reached. After another three months, the final wave of interviews began, including only
102 respondents with whom at least one previous interview had been completed (Fig 1).

103 **Fig 1: Enrollment and participation in NYC e-cigarette, or vaping, associated lung injury**
104 **(EVALI) interviews, waves 1–3.**

105 Interview questions included age, sex assigned at birth, symptoms, health conditions,
106 healthcare use, insurance coverage, substance use, functional, student, and employment status.
107 Effects of EVALI on finances were mostly categorical and adapted from CDC’s EVALI case
108 report form [8] and validated surveys. This included the NYC Community Health Survey, [9]
109 Youth Risk Behavior Survey, [10] and National Survey on Drug Use and Health [11].
110 Abbreviated interviews included a shorter set of primarily open-ended questions that covered the
111 same content areas. At the end of each interview, we asked if respondents had anything else to
112 share about their experience or consequences of their lung injury on their lives.

113 Information about hospitalization, including duration of stay and intubation status, were
114 abstracted from medical records, along with sex, age, and race and ethnicity. We did not include
115 interview questions about race and ethnicity, because we had intended to use NYS DOH case
116 interview data from the initial outbreak. However, these data were missing for most NYC
117 residents with an EVALI diagnosis, something we did not learn until the follow-up interviews

118 were already completed. Instead, we used electronic medical record data to supplement this
119 information because provider reports, which were used to identify cases did not include race or
120 ethnicity.

121 Data were stored in restricted access file folders on secure agency share drives. This
122 activity was reviewed by CDC and DOHMH Institutional Review Boards and was determined to
123 be non-research public health surveillance. This study was reviewed by CDC and was conducted
124 consistent with federal law and CDC policy.¹

125 **Data analyses**

126 Data from the first wave of interviews using the full interview form and data from those
127 interviewed for the first time during the second wave using the abbreviated interview form, were
128 merged and recoded as first interview. Open-ended responses from the abbreviated interviews
129 were coded to match the categories from the full interview form, when possible. All three waves
130 of interviews were coded as third interview, regardless of the number of prior interviews.
131 Baseline differences between respondents and nonrespondents were assessed with Chi-square
132 and Fisher's exact tests using SAS[®] version 9.4 (SAS Institute, Inc., Cary, North Carolina).
133 Symptoms, health conditions, healthcare use, substance use patterns, functional status, and
134 effects of EVALI on finances were also summarized for each wave of interviews. Symptom
135 trends among the respondents who completed all three interviews were summarized to assess for
136 resolution over time. Two investigators reviewed free text comments for additional themes and
137 to provide context for the quantitative data. Because of missing data, race and ethnicity were not
138 used in any analyses.

139

¹ 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq

140 **Results**

141 **Baseline characteristics**

142 In 2019, a total of 53 NYC residents received an EVALI diagnosis. Most were male
143 (72%); median age was 23 years (range: 15–63 years). Four (8%) died of EVALI (Table 1).
144 Decedents were mostly male (n = 3; 75%) and had a median age of 28 years (range: 17–34
145 years). Two decedents had been hospitalized (mean = 13 days) and intubated; one decedent died
146 at home, and one decedent presented to the emergency department in cardiac arrest and did not
147 survive.

148 **Table 1: Demographic characteristics and hospitalization status among New York City residents who received a diagnosis of e-**
 149 **cigarette, or vaping, associated lung injury (EVALI) in 2019**

Characteristic	Decedents		Non-Respondents vs Respondents					First interview*		Second interview**		Third interview**	
			Nonrespondents (never reached)		Respondents (any round)		Nonrespondents vs Respondents						
	N = 4	%	N = 16	%	N = 33	%	P value	N = 33	%	N = 14	%	N = 18	%
Sex							0.70						
Male	3	75	12	75	23	70		23	70	11	79	10	56
Female	1	25	4	25	10	30		10	30	3	21	8	44
Age													
Age (yrs) at diagnosis, median (range)	28 (17–34)		23 (15–39)		23 (16–63)			23 (16–63)		25 (16–63)		28 (16 – 63)	
Age (yrs) groups at diagnosis							0.723***						
13–17	1	25	2	13	5	15		5	15	2	14	2	11
18–24	1	25	8	50	13	39		13	39	5	36	4	22
25–34	2	50	2	13	8	24		8	24	3	21	6	33
35–44	0	--	4	25	5	15		5	15	3	21	4	22
≥45	0	--	0	--	2	6		2	6	1	7	2	11
Insurance status													
Employer-based or private								18	55	10	71	11	61

Medicaid or Medicare								10	30	4	29	5	28
Other								4	12	0	--	0	--
Uninsured								0	--	0	--	2	11
Employment status													
Employed								23	70	7	50	14	78
Unemployed								8	24	7	50	4	22
Educational status													
Attending school								10	30	3	21	4	22
Time (months) from diagnosis to interview round													
Median (range)								8 (5–15)		11 (9–15)		17 (15 – 19.0)	
Hospitalization status													
Initially hospitalized	3	75	16	100	31	94	0.177	31	94	13	93	17	94
Intubation	2	50	3	19	3	9	0.333	3	9	2	14	3	17
Days hospitalized, median (range)	9 (1–17)		6 (1–30)		7 (1–13)			7 (1–13)		9 (1–13)		7.5 (1 – 13)	
≥7 days	1	25	4	25	15	46	0.122	15	45	7	50	10	56

*Refers to the time between EVALI diagnosis/discharge and first interview

**Refers to the 3 months before the interview round

***By Fishers Exact Test

Missing Values were excluded from the table

151 **Interview participation and respondent demographics**

152 Interviews occurred from 5 to 19 months after initial hospitalization or injury, at a
153 median of 8, 11, and 17 months for each interview wave. Among 49 potential respondents, 33
154 (67%) completed the first interview (24 in the first wave and 9 during the second wave), 14
155 (29%) completed the second interview, and 18 (37%) completed the third interview; overall, 33
156 (67%) respondents completed ≥ 1 interview and 22 (45%) completed ≥ 2 interviews. Ten
157 respondents (20%) completed interviews during all three waves (Fig 1).

158 Respondents (N = 33; 67%) and nonrespondents (N = 16; 33%) did not significantly
159 differ by sex, age group at diagnosis, intubation status, hospitalization status, or length of
160 hospitalization (Table 1). Respondents were mostly male (n = 23; 70%), had a median age of 23
161 years (range: 16–63 years), were hospitalized (n = 31; 94%) for a median of 6 days (range: 0–13
162 days), and were not intubated (n = 30; 91%). Approximately half of respondents reported that at
163 the time of hospitalization or diagnosis they had employer-based or private health insurance (n =
164 18; 55%). Race and ethnicity were incomplete for 16 of 49 surviving NYC residents who
165 received an EVALI diagnosis in 2019 (33% of potential respondents) and data were not used.

166 In terms of substance use patterns, 100% of respondents reported vaping, with either
167 tetrahydrocannabinol (THC) (88%), nicotine (49%), or cannabidiol (CBD) (9%) before diagnosis
168 (Table 2). Some respondents (15%–29%) reported recent vaping at each interview, and most
169 respondents (58%–93%) reported recent non-vaped (e.g., smoked or edible) cannabinoid use. A
170 limited number of respondents reported smoking cigarettes (0%–6%) or other tobacco products
171 (0%–11%).

172 **Table 2: Vaping, e-cigarette, and substance use among New York City e-cigarette, or vaping, associated lung injury (EVALI)**

173 **prospective follow-up respondents**

Characteristic	Prior to EVALI diagnosis		First interview*		Second interview**		Third interview**	
	N = 33	%	N = 33	%	N = 14	%	N = 18	%
Vaped or used e-cigarettes	33	100	5	15	4	29	3	17
Nicotine	16	49	6	18	2	14	2	11
Marijuana or THC	29	88	2	6	2	14	2	11
CBD	3	9	1	3	0	--	0	--
General substance use								
Cigarettes			2	6	0	--	1	6
Other tobacco products			2	6	0	--	2	11
Hookah or Waterpipe			1	3	1	7	1	6
Non-Vaped Cannabinoids			19	58	13	93	13	72
Smoked or Dabbed					9	64	7	39
Other substance (heroin; cocaine; methamphetamines; huffing [paint or glue]; other)			2	6	0	--	4	22
Alcohol use								
≥ 1 drink in last 30 days					9	64	12	67
Binge drank in last 30 days ¹					1	7	3	17

*Refers to the time between EVALI diagnosis and discharge and first interview.

**Refers to the 3-month period before the interview.

¹Binge refers to ≥4 drinks in a row for females, ≥5 drinks in a row for males.

Missing values were excluded from the table.

175 Preexisting and Newly Diagnosed Health Conditions

176 Respondents reported preexisting mental health conditions (49%), including anxiety
 177 (36%), depression (24%) and other conditions (15%); asthma (27%), cardiovascular (12%)
 178 conditions, including hypertension, hyperlipidemia, and heart disease; and diabetes (3%). At first
 179 interview, respondents reported receiving new diagnoses of anxiety (27%), depression (15%),
 180 other mental health conditions (3%), asthma (9%), other respiratory (3%) or cardiovascular (9%)
 181 conditions, and diabetes (3%) (Table 3). Overall, 16 respondents (49%) reported receiving a new
 182 diagnosis during the follow-up period.

183 **Table 3: Clinical characteristics and effects of e-cigarette, or vaping, associated lung injury**
 184 **(EVALI) diagnosis among respondents**

Characteristic	Before EVALI diagnosis		First interview*		Second interview**		Third interview**	
	N = 33	%	N = 33	%	N = 14	%	N = 18	%
Symptoms								
Chest pain	1	3	7	21	1	7	4	22
Constitutional (fevers, tiredness, decreased appetite)	3	9	11	33	2	14	5	28
Gastrointestinal (nausea, vomiting, diarrhea, bloating, or abdominal pain)	3	9	10	30	4	29	9	50
Headache	7	21	10	30	3	21	5	28
Mental health (little interest, depressed, bipolar symptoms, anxiety, anger, panic, insomnia, or survivor's guilt)	4	12	6	18	5	36	6	33
Respiratory (SOB, pleuritic chest pain, or cough)	4	12	17	52	7	50	4	22
Other symptoms (hair loss, muscle atrophy, loss of singing voice, or other)	0	--	3	9	1	7	2	11
Health conditions¹								

Behavioral (ADD, ADHD, Anxiety, Depression, PTSD, or substance use)	16	49	9	27	2	14	0	--
Anxiety	12	36	9	27	1	7	0	--
Depression	8	24	5	15	0	--	0	--
Other	5	15	1	3	1	7	0	--
Cardiovascular (high blood pressure, cholesterol, or heart disease)	4	12	3	9	2	14	1	6
COVID-19			1	3	0	--	1	6
Diabetes	1	3	1	3	0	--	0	--
Respiratory (Sleep apnea, asthma, or COPD)	9	27	4	12	1	7	0	--
Asthma	9	27	3	9	1	7	0	--
Other (other conditions, arthritis, or chronic headaches)	7	21	3	9	3	21	1	6
Health care utilization ≥1 visit								
Any healthcare provider			30	91	13	93	15	83
Cardiologist			5	46	1	7	2	11
Dentist			2	6	1	7	1	6
Mental health provider			4	12	6	43	3	17
Primary care provider			18	55	4	29	9	50
Pulmonologist			27	79	2	14	1	6
Urgent Care provider			3	9	2	14	2	11
Other health care provider			3	9	6	43	6	33
Medication use								
Corticosteroid use			23	70	0	--	0	--
Effects								
Help with personal care needs			4	12	2	14	0	--
Help with routine needs			9	27	1	7	2	11
Financial problems			10	30	0	--	1	6

¹Refers to that health condition being newly diagnosed in the period noted below for first interview, second interview, and third interview.

*Refers to the time between EVALI hospitalization discharge (for those hospitalized) or diagnosis (for those not hospitalized) and first interview.

**Refers to the 3month period before the interview.

Missing values were excluded from the table

185

186 **Symptoms**

187 Between EVALI diagnosis and first interview, and during the three months before the
188 second wave of interviews, respiratory symptoms were commonly reported (50%); however,
189 gastrointestinal symptoms were most commonly reported (50%) during the three months before
190 the third wave of interviews.

191 Among the 10 respondents who completed all three interviews, gastrointestinal
192 symptoms were the most common (60%), and half (30%) remained unresolved by the third
193 interview (Fig 2). Similarly, approximately half of respiratory, constitutional, and chest pain
194 symptoms remained unresolved by the third interview.

195 **Fig 2. New symptoms after receiving EVALI diagnosis among the respondents who**
196 **participated in all three interviews.**

197 *Mental health includes attention deficit disorder (ADD), attention deficit hyperactivity disorder
198 (ADHD), anxiety, depression, or post-traumatic stress disorder (PTSD); respiratory includes
199 sleep apnea, asthma, or chronic obstructive pulmonary disorder; constitutional includes fevers,
200 tiredness, or decreased appetite; and gastrointestinal includes nausea, vomiting, diarrhea,
201 bloating, or abdominal pain.
202

203 **Effects on personal function and finances**

204 In the months after an EVALI diagnosis, nine of 33 respondents (27%) required help with
205 routine needs such as everyday household chores, four (12%) required help with personal care
206 such as bathing or eating, and 10 (30%) reported financial problems because of EVALI. By the
207 third wave of interviews, only two (11%) respondents reported requiring help with routine needs,
208 no respondents required help with personal care, and one (6%) respondent reported recent
209 financial problems because of EVALI.

210 Most (70%, n = 23) respondents were employed and 33% (n = 11) were in school when
211 diagnosed. All students returned to school or graduated, and 74% of those employed (n = 17)
212 returned to the same job after their diagnosis. Nine (53%) of those who returned to the same job
213 missed from one week to one month of work; 35% (n = 6) missed one week of work or less; and

214 6% (n = 1) missed from one to three months of work. Accommodations were made for 18% (n =
215 3) on return to work and 30% (n = 3) on return to school.

216 **Healthcare use**

217 Between diagnosis or hospital discharge and first interview, 91% of respondents had
218 received treatment by a health care provider, most often a pulmonologist (79%) or an ambulatory
219 primary care provider (55%). Respondents continued to interact with health care providers, with
220 93% and 83% receiving treatment from healthcare providers during the three months preceding
221 second and third interviews respectively; they most frequently visited mental health providers
222 (43% and 17%) and primary care providers (29% and 50%) during this time frame.

223 **Respondent commentary on EVALI**

224 Qualitative responses were received from 23 (70%) of the 33 study respondents, nine
225 (40%) of whom were female. During the three waves of interviews, 14 (52%) respondents
226 commented once, nine (39%) commented twice and two (8%) commented during all three
227 interviews. This provided a total of 36 statements addressing current concerns, recovery, and
228 long-term health outcomes (data not shown).

229 During the three interview waves, 10 of 23 respondents (43.5%) noted change in outlook
230 about e-cigarette or vaping product use, specific product types, or health risks. Six respondents
231 (26%) stated that they had stopped e-cigarette or vaping product use. However, three (13%)
232 continued to report smoking cannabis, use of what they termed natural products or obtaining
233 products from a medical cannabis dispensary. Eight (34.7%) respondents suggested they had
234 recovered, five (22%) suggested they were still experiencing symptoms from injury or treatment.
235 Four (18%) suggested the experience had been traumatizing and six (26%) expressed variable

236 thoughts about the lack of effect their injury had on friends, lack of regulation, the need for
237 provider education, or had no other significant concerns.

238 **Discussion**

239 Respondents reported symptoms throughout the follow-up period, and approximately half
240 reported new-onset morbidity. Although many symptoms resolved, especially during the latter
241 part of the follow-up period, our qualitative findings indicate that changes to vaping behavior
242 and mindset endured. The periodic interviews allowed us to collect data regarding symptoms,
243 and effects on education and employment, although the COVID-19 pandemic likely played a role
244 in some of the mental health symptoms and employment challenges reported.

245 CDC's clinical guidance recommends outpatient primary care or pulmonary specialist
246 follow up, optimally within 48 hours of discharge, and social support and access to mental health
247 and substance use disorder services [12]. Although many of our respondents received a diagnosis
248 before the October 2019 guidance release, overall treatment was consistent with this guidance.
249 Almost all respondents had been treated by ≥ 1 health care providers by their first interview. Per
250 CDC, cardiac disease, chronic pulmonary disease, diabetes, and older age were risk factors for
251 higher morbidity and mortality among those who received an EVALI diagnosis. Nationwide,
252 anxiety, depression, attention deficit disorder (ADD), attention deficit hyperactivity disorder
253 (ADHD), and other mental and behavioral health conditions were common among EVALI
254 patients [2, 13]. Our findings were consistent with CDC's nationwide findings; however, the
255 mortality rate in NYC (7.5%) among those who received a diagnosis in 2019 was higher than the
256 national rate (2.4%), which included cases through February 2020.

257 Approximately half (49%) of respondents had preexisting behavioral health conditions.
258 The rate of preexisting depression in our cohort (24%) was approximately three times the overall

259 rate in NYC (9%).[14] National survey data suggest that self-medication (e.g., use of alcohol,
260 cannabis, or nicotine to address anxiety) for mental health conditions is not uncommon [15].
261 Approximately half of respondents reported new diagnoses for other physical or behavioral
262 health conditions during the follow-up period. The possibility exists that some of these new
263 diagnoses were preexisting, but undiagnosed conditions. Young adults generally use the health
264 care system less than other age groups overall, but have higher rates of emergency department
265 use [16]. Our findings indicate that closer medical follow-up after EVALI may have facilitated
266 additional diagnoses and improved care. EVALI might have also been a contributing factor to
267 some of the newly diagnosed behavioral health and respiratory conditions. Fewer than half of our
268 respondents were treated by mental health providers. However, supporting recovery from
269 EVALI will require some degree of mental health follow-up and substance use treatment to
270 reduce the risk for reinjury or other secondary pulmonary complications. More consistent use of
271 outpatient services for young adults might also prevent or reduce severity of future EVALI cases.

272 Two other published studies have looked at long-term outcomes after EVALI. Blagev et
273 al tracked 73 patients in Utah through medical records abstraction and conducted clinical
274 screening activities at 12-months post-diagnosis [17]. Triantafyllou et al retrospectively reviewed
275 electronic medical records of 41 patients who received an EVALI diagnosis and admitted to any
276 of the University of Pittsburgh Medical Center hospitals [18]. Both studies reported similar age
277 and sex distributions, rates of behavioral health and cardiovascular disease, and proportions of
278 respondents using e-cigarettes with THC or nicotine, consistent with our interview findings.
279 Blagev et al and our interviews reported similar median lengths of stay in the hospital (5 and 6
280 days respectively). Our findings contribute prospective data from a third jurisdiction at multiple
281 timepoints on the physical, mental, and functional health of respondents, and social effects. One

282 main difference between our findings and those from the other two studies is that Triantafyllou et
283 al included hospital admissions through September 2020 and Blagev et al included diagnoses
284 through August 2021. However, our respondents all received an EVALI diagnosis in 2019. Thus,
285 our time frame excluded the potential for COVID-19 to be a factor in the initial hospitalization
286 and case identification. In addition, compared with Triantafyllou et al, a higher proportion of our
287 respondents reported a history of asthma (27% vs 8%). Among our respondents, although only
288 some reported continued vaping (15%–29% across waves), most reported using non-vaped
289 cannabinoids, often by smoking or dabbing (i.e., inhaling a smoked or aerosolized concentrated
290 cannabis resin). Participants in the Blagev et al study were more likely to report nicotine
291 consumption (vaped and smoked) and cannabis vaping after receiving their EVALI diagnosis
292 than our respondents.

293 **Limitations**

294 The limited number of potential respondents ($n = 48$) and the nonresponse rate (32%)
295 suggests that the findings might not have captured the full range of post-discharge health
296 sequelae among the potential respondents. However, respondents and nonrespondents did not
297 differ by sex, age, initial hospitalization status, or length of stay. Economic or other
298 circumstantial differences imposed by the COVID-19 pandemic might have been a barrier to
299 participation or with ongoing follow-up. The conclusions also involved self-reported findings
300 from a local municipal population, which cannot be generalized to the broader population
301 affected by EVALI, especially given the variable state and local regulatory environment for
302 cannabis and e-cigarettes. A robust effort was made to abstract race and ethnicity information
303 from available electronic health records; however, these data were found to be incomplete and
304 inadequate for identifying associated disparities [19]. Although the interviews were confidential

305 and used nonjudgmental survey questions administered by experienced interviewers, they were
306 not anonymous. The possibility exists that some persons responded to the surveys based on
307 perceptions of social desirability, need to share their story for benefit of others, or to affirm a
308 positive outcome with their health. Because of DOHMH staffing constraints during the
309 pandemic, some respondents also did not speak with the same investigator each time.

310 **Public Health Implications**

311 Limited regulation and oversight of new consumer products, including ingredients in
312 nicotine and cannabis products, contributed to the EVALI outbreak.[20] These products continue
313 to evolve, which presents a challenge to the development and communication of health risk
314 information. Ongoing surveillance is particularly crucial, because cannabis was legalized for
315 adult use in NYS in 2021, and new products continue to emerge. Although vitamin E acetate has
316 been identified as a contributor to EVALI, certain respondents vaped only nicotine products
317 before receiving a diagnosis, which are not known to contain vitamin E acetate. Consistent with
318 the conclusion reached by other researchers, we lack sufficient information about vaping product
319 constituents and excipients involved in each lung injury to provide specific new warning to the
320 public or establish more protective regulations for manufacturers.¹

321 Given the rapid evolution of products, periodic follow-up with a group of consumers
322 might help supplement other traditional modes of surveillance. For example, one respondent
323 inquired about risks for nicotine-free vaping products being marketed as wellness products or
324 personal diffusers, which claimed to deliver essential oils. This led NYC DOHMH to update
325 communications for the public, retailers, and clinicians to include these products.

326 NYC DOHMH maintains some active and passive surveillance of EVALI, identifying
327 approximately three or four cases of EVALI per month. As the COVID-19 pandemic progressed

328 during spring of 2020, we noted that the clinical assessment of patients began to evolve, often
329 with repeated COVID-19 testing, which highlighted the continued challenge of recognizing and
330 diagnosing EVALI. Detailed substance use histories often led to the ultimate diagnosis and
331 appropriate treatment. Subsequently, state and local agencies collaborated to develop guidance
332 informing health care providers that EVALI cases continue to occur and should be considered
333 alongside other etiologies.[21]

334 The preponderance of preexisting and new mental health diagnoses among respondents
335 also suggests that clinical follow up by behavioral health providers might be beneficial for
336 addressing substance use and psychological trauma of injury, hospitalization, and any emotional
337 and social adjustments to long-term physical impairments suffered by patients.

338

339 **Conclusion**

340 NYC residents with EVALI reported symptoms throughout the follow-up period, and
341 approximately half reported new-onset morbidity. These findings have guided clinician
342 education and public health messaging and might influence e-cigarette policy and individual
343 health behaviors. Findings and follow-up have also guided surveillance efforts, both for other
344 emerging products and for emerging injuries or illnesses that might result in chronic disease.
345 Other studies are needed to understand long-term health of EVALI cases and to more fully
346 understand causes of EVALI associated with various vaping products.

347

348 **Acknowledgments**

349 We wish to acknowledge Tabassum Z. Insaf, PhD, Monica P. Nordstrom, MSPH, from
350 the New York State Department of Health, and Philip C. DiSalvo, MD, of the Carle Illinois

351 College of Medicine, formerly of the New York City Department of Health’s Poison Control
352 Center and the staff of the Poison Control Center, for their exceptional assistance supporting our
353 lung injury surveillance and identification of New York City EVALI cases in 2019. We also
354 acknowledge Kim Kessler, JD, Assistant Commissioner of the Bureau of Chronic Disease
355 Prevention (BCDP), New York City Department of Health and Jennifer G. Wright, DVM, MPH
356 from the Centers for Disease Control and Prevention’s Division of Partnership Support (PHIC)
357 and Division of Workforce Development (DWD) for their detailed manuscript reviews, edits and
358 comments. We also thank Lourdes M. Cifuentes, MPH, of the Food Bank for New York City, a
359 former BCDP staff member, who conducted interviews and supported the data collection process
360 during the first wave of interviews.

361

362 **References**

- 363 1. U.S. Department of Health and Human Services, Centers for Disease Control and
364 Prevention. Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping,
365 Products 2020 [updated August 3, 2021. Available from:
366 [https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html#map-](https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html#map-cases)
367 [cases](https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html#map-cases)).
- 368 2. Evans ME, Twentyman E, Click ES, Goodman AB, Weissman DN, Kiernan E, et al.
369 Update: Interim Guidance for Health Care Professionals Evaluating and Caring for Patients with
370 Suspected E-cigarette, or Vaping, Product Use-Associated Lung Injury and for Reducing the
371 Risk for Rehospitalization and Death Following Hospital Discharge - United States, December
372 2019. *MMWR Morb Mortal Wkly Rep.* 2020;68(5152):1189-94.
- 373 3. Overbeek DL, Kass AP, Chiel LE, Boyer EW, Casey AMH. A review of toxic effects of
374 electronic cigarettes/vaping in adolescents and young adults. *Crit Rev Toxicol.* 2020;50(6):531-
375 8.
- 376 4. U.S. Department of Health and Human Services, Centers for Disease Control and
377 Prevention. About Electronic Cigarettes (E-Cigarettes) [Available from:
378 https://www.cdc.gov/tobacco/basic_information/e-cigarettes/about-e-cigarettes.html.
- 379 5. Belok SH, Parikh, R., Bernardo, J. et al. . E-cigarette, or vaping, product use-associated
380 lung injury: a review. *Pneumonia* 2020(12):12.
- 381 6. Jatlaoui TC WJ, Kabbani S, et al. . Update: Interim Guidance for Health Care Providers
382 for Managing Patients with Suspected E-cigarette, or Vaping, Product Use–Associated Lung
383 Injury — United States, November 2019. *MMWR Morb Mortal Wkly Rep.* 2019(68):1081-6.

- 384 7. U.S. Department of Health and Human Services, Centers for Disease Control and
385 Prevention. 2019 LUNG INJURY SURVEILLANCE PRIMARY CASE DEFINITIONS. 2019.
- 386 8. U.S. Department of Health and Human Services, Centers for Disease Control and
387 Prevention. Lung Injury Associated with E-cigarette Use or Vaping | National Case Report Form.
388 2019.
- 389 9. NYC Department of Health and Mental Hygiene. Community Health Survey Public Use
390 Data [Available from: [https://www.nyc.gov/site/doh/data/data-sets/community-health-survey-
391 public-use-data.page](https://www.nyc.gov/site/doh/data/data-sets/community-health-survey-public-use-data.page).
- 392 10. U.S. Department of Health and Human Services, Centers for Disease Control and
393 Prevention. 2019 Youth Risk Behavior Survey Questionnaire.
- 394 11. U.S. Department of Health and Human Services, Substance Abuse and Mental Health
395 Services Administration, Center for Behavioral Health Statistics and Quality. 2018 National
396 Survey on Drug Use and Health Public Use File Codebook. Retrieved March 8, 2024 from
397 [https://www.datafiles.samhsa.gov/sites/default/files/field-uploads-protected/studies/NSDUH-
398 2018/NSDUH-2018-datasets/NSDUH-2018-DS0001/NSDUH-2018-DS0001-info/NSDUH-
399 2018-DS0001-info-codebook.pdf](https://www.datafiles.samhsa.gov/sites/default/files/field-uploads-protected/studies/NSDUH-2018/NSDUH-2018-datasets/NSDUH-2018-DS0001/NSDUH-2018-DS0001-info/NSDUH-2018-DS0001-info-codebook.pdf)
- 400 12. David A. Siegel TCJ, Emily H. Koumans, Emily A. Kiernan, Mark Layer, Jordan E.
401 Cates, Anne Kimball, David N. Weissman, Emily E. Petersen, Sarah Reagan-Steiner, Shana
402 Godfred-Cato, Danielle Moulia, Erin Moritz, Jonathan D. Lehnert, Jane Mitchko, Joel London,
403 Sherif R. Zaki, Brian A. King, Christopher M. Jones, Anita Patel, Dana Meaney Delman, Ram
404 Koppaka, Lung Injury Response Clinical Working Group; Lung Injury Response
405 Epidemiology/Surveillance Group. Update: Interim Guidance for Health Care Providers
406 Evaluating and Caring for Patients with Suspected E-cigarette, or Vaping, Product Use
407 Associated Lung Injury — United States, October 2019. DOI:
408 <http://dx.doi.org/10.15585/mmwr.mm6841e3external> icon. MMWR Morb Mortal Wkly Rep.
409 2019;68:919–27.
- 410 13. Marrocco A, Singh D, Christiani DC, Demokritou P. E-cigarette vaping associated acute
411 lung injury (EVALI): state of science and future research needs. Crit Rev Toxicol.
412 2022;52(3):188-220.
- 413 14. NYC Department of Health and Mental Hygiene. Community Health Survey 2017
414 [Available from: [https://a816-
415 health.nyc.gov/hdi/epiquery/visualizations?PageType=ts&PopulationSource=CHS&Topic=3&S
416 ubtopic=20](https://a816-health.nyc.gov/hdi/epiquery/visualizations?PageType=ts&PopulationSource=CHS&Topic=3&Subtopic=20).
- 417 15. Sarvet AL, Wall MM, Keyes KM, Olfson M, Cerdá M, Hasin DS. Self-medication of
418 mood and anxiety disorders with marijuana: Higher in states with medical marijuana laws. Drug
419 Alcohol Depend. 2018;186:10-5.
- 420 16. Investing in the Health and Well-Being of Young Adults. Washington (DC): National
421 Academies Press (US); 2015.
- 422 17. Blagev DP, Callahan SJ, Harris D, Collingridge DS, Hopkins RO, Eve JR, et al.
423 Prospectively Assessed Long-Term Outcomes of Patients with E-Cigarette- or Vaping-associated
424 Lung Injury. Ann Am Thorac Soc. 2022;19(11):1892-9.
- 425 18. Triantafyllou GA, Tiberio PJ, Zou RH, Lynch MJ, Kreit JW, McVerry BJ, et al. Long-
426 term outcomes of EVALI: a 1-year retrospective study. Lancet Respir Med. 2021;9(12):e112-e3.
- 427 19. Cook LA, Sachs, J., & Weiskopf, N. G. . The quality of social determinants data in the
428 electronic health record: a systematic review. Journal of the American Medical Informatics
429 Association : JAMIA. 2021;29(1):187-96.

- 430 20. Cao DJ, Aldy K, Hsu S, McGetrick M, Verbeck G, De Silva I, et al. Review of Health
431 Consequences of Electronic Cigarettes and the Outbreak of Electronic Cigarette, or Vaping,
432 Product Use-Associated Lung Injury. *J Med Toxicol.* 2020;16(3):295-310.
433 21. Letter to Health Care Providers. NYS Office of Cannabis Management; 2022.
-




Figure 1

New symptoms among ten respondents who participated in all three interviews




Figure 2